Quote:
AstraZeneca PLC executives have struggled to pull together the full data necessary to apply for U.S. approval of its Covid-19 shot, according to people familiar with the matter, further delaying its efforts to secure the Food and Drug Administration’s go-ahead.
The company said last month that it would apply for what is known as emergency use authorization for its vaccine by mid-April. It has recently told U.S. officials it might need until mid-May to finish its application for an FDA review, according to one of these people.
[...]
An AstraZeneca spokeswoman said this week that the company is progressing in its preparation of the FDA submission but declined to give a timetable.
Article touches on the signaling aspect, but I don't believe it is as consequential—from a global perspective—as they're making it out to be, given the demand for all covid vaccines (including Sputnik's and SinoVac's); desperation is a powerful motivator. Don't really think this is all that good for Janssen/J&J either.